(Q24655964)

English

Multiple myeloma

scientific article

In more languages

Statements

scholarly article

0 references

1 reference

Europe PubMed Central

Multiple myeloma (English)

0 references

0 references

1

object named as

Robert A Kyle

0 references

S. Vincent Rajkumar

2

object named as

S Vincent Rajkumar

0 references

language of work or name

0 references

publication date

15 March 2008

0 references

0 references

111

0 references

2962-72

0 references

6

0 references

The nature of Bence-Jones proteins. Chemical similarities to polypetide chains of myeloma globulins and normal gamma-globulins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

7 April 2017

Thalidomide is an inhibitor of angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

7 April 2017

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

7 April 2017

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

7 April 2017

The ubiquitin-proteasome proteolytic pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

7 April 2017

Case of Mollities and Fragilitas Ossium, accompanied with urine strongly charged with animal matter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Remarks on the pathology of mollities ossium; with cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

ELECTROPHORETIC PATTERNS OF NORMAL AND PATHOLOGICAL HUMAN BLOOD SERUM AND PLASMA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

A comparison of allografting with autografting for newly diagnosed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Prevalence of monoclonal gammopathy of undetermined significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Thalidomide: tragic past and promising future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Treatment of plasma cell dyscrasias with thalidomide and its derivatives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

THALIDOMIDE (N-PHTHALOYLGLUTAMIMIDE) IN THE TREATMENT OF ADVANCED CANCER.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Multiple myeloma: an odyssey of discovery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Melphalan in multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

A controlled trial of urethane treatment in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 September 2017

Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

30 May 2018

Electrophoresis of proteins on filter paper

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

30 May 2018

Inhibition of Rabbit Brain Prolyl Endopeptidase by N‐Benzyloxycarbonyl‐Prolyl‐Prolinal, a Transition State Aldehyde Inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

30 May 2018

Response rate and survival in myeloma patients receiving prednisone alone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

30 May 2018

Identical-twin (syngeneic) marrow transplantation for hematologic cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

30 May 2018

VAD-based regimens as primary treatment for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

30 May 2018

Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

30 May 2018

Urethane and stilbamidine in multiple myeloma report on two cases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

AN ELECTROPHORETIC STUDY OF IMMUNE SERA AND PURIFIED ANTIBODY PREPARATIONS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2265446

28 November 2018

[Clinical experiences with sarcolysin in neoplastic diseases]

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple myeloma treated with high dose intravenous melphalan

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806)

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies on conditions associated with disturbed gamma globulin formation (gammopathies)

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, vincristine, prednisone, and BCNU

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DIRECT IMMUNOELECTROPHORESIS

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CLINICAL EXPERIENCES WITH THALIDOMIDE IN PATIENTS WITH CANCER

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple-myeloma proteins. III. The antigenic relationship of Bence Jones proteins to normal gammaglobulin and multiple-myeloma serum proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal gammopathy of undetermined significance. Natural history in 241 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone marrow transplantation in multiple myeloma: report from the European Cooperative Group for Bone Marrow Transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Method permitting the combined study of the electrophoretic and the immunochemical properties of protein mixtures; application to blood serum]

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identical twin marrow transplantation in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18332230

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

THALIDOMIDE AND CONGENITAL ABNORMALITIES

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2007-10-078022

7 January 2021

based on heuristic

inferred from DOI database lookup

A new apparatus for electrophoretic analysis of colloidal mixtures

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2007-10-078022

7 January 2021

based on heuristic

inferred from DOI database lookup

On a New Substance Occurring in the Urine of a Patient with Mollities Ossium

1 reference

https://api.crossref.org/works/10.1182%2FBLOOD-2007-10-078022

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1182/BLOOD-2007-10-078022

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24655964&oldid=1475531406"